彼得·洛夫特斯报道
在与辉瑞争夺一项减肥药物初创公司失利后,诺和诺德将更加依赖自身的研究实验室开发新药,尽管它仍可能继续寻求其他交易。以下是其可能的下一步:
-- Wegovy药丸。诺和诺德近期的重点是推出Wegovy的药丸形式,这是一种自2021年首次以每周注射形式推出的热门减肥药。诺和诺德已申请美国食品和药物管理局的批准,并预计在年底前会有决定。
-- 下一代注射剂。诺和诺德还研发了一种名为CagriSema的注射式组合抗肥胖药物,计划明年寻求监管批准。
-- 更多交易尝试。分析人士普遍认为竞争对手礼来拥有更好的下一代减肥药物管线。诺和诺德在财务上具备强大实力,预计会继续寻找收购机会,以充实其产品管线。
诺和诺德的美国存托凭证周一上涨近1%。
(完)道琼斯新闻通讯社
2025年11月10日 10:36 ET(15:36 GMT)
版权所有 © 2025 道琼斯公司。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.